Patents by Inventor Jingyun Ji

Jingyun Ji has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lentiviral vector capable of directly reflecting type I interferon response, preparation method thereof, and applications thereof
    Patent number: 11384366
    Abstract: Provided are a method for establishing a lentiviral vector system capable of directly reflecting type I interferon response, and applications thereof. The method for establishing the lentiviral vector system comprises: cutting a Gaussia luciferase at the position of amino acid 109, removing 16 amino acids from N-terminus, and cloning the two polypeptides into a lentiviral vector to form a lentiviral BiLC expression vector; and cloning a shuttle plasmid of pEntry-IRF3 or pEntry-IRF5 or pEntry-IRF7 by homologous recombination into the lentiviral BiLC expression vector, so as to construct a lentiviral vector IRF3-BiLC or IRF5-BiLC or IRF7-BiLC capable of directly reflecting type I interferon response.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: July 12, 2022
    Assignee: Fantasia Biopharma (Zhejiang) Co. Ltd.
    Inventors: Frank XiaoFeng Qin, Fei Wu, Zining Wang, Jingyun Ji, Jing Xia
  • Lentiviral Vector Capable of Directly Reflecting Type I Interferon Response, Preparation Method Thereof, and Applications Thereof
    Publication number: 20190119700
    Abstract: Provided are a method for establishing a lentiviral vector system capable of directly reflecting type I interferon response, and applications thereof. The method for establishing the lentiviral vector system comprises: cutting a Gaussia luciferase at the position of amino acid 109, removing 16 amino acids from N-terminus, and cloning the two polypeptides into a lentiviral vector to form a lentiviral BiLC expression vector; and cloning a shuttle plasmid of pEntry-IRF3 or pEntry-IRF5 or pEntry-IRF7 by homologous recombination into the lentiviral BiLC expression vector, so as to construct a lentiviral vector IRF3-BiLC or IRF5-BiLC or IRF7-BiLC capable of directly reflecting type I interferon response.
    Type: Application
    Filed: March 29, 2017
    Publication date: April 25, 2019
    Applicant: Suzhou Ultralmmune Co., Ltd.
    Inventors: Frank XiaoFeng Qin, Fei Wu, Zining Wang, Jingyun Ji, Jing Xia